Strategic workshops designed to align clinical development with global commercial reality. In the new era of European Joint Clinical Assessments (JCA) and International Reference Pricing (MFN), a drug's scientific success is no longer enough to guarantee its commercial value. I offer three specialized briefings to help biotechs and investors identify "Non-Recoverable" evidence gaps before they trigger a valuation collapse.

1. The JCA Landscape & Regulatory Intersection

Focus: The Double Disruption of 2025/2026

This briefing addresses the "Mindset Divide" between proving safety to regulators and proving relative value to payers. We explore how the JCA "PICO Explosion" replaces a single EMA filing with 27 different national treatment realities.

• Key Insight: Why securing market authorization and national reimbursement must now happen simultaneously.
• Target Audience: Clinical Development Leads, Regulatory Affairs, and C-Suite Executives.

2. Evidence Gap Analysis & Risk Mitigation

Focus: PICO Shadowing and the $500M Valuation Gap

A deep dive into the methodology of "Evidence Shadowing"—predicting national requirements 24 months before filing. We quantify how sub-optimal trial designs lead to "Low Added Benefit" ratings and immediate price erosion.

• Key Insight: Identifying "Non-Recoverable" design flaws like missing Quality of Life (QoL) data or unbridgeable comparators.
• Target Audience: Investor Deal Teams, Portfolio Managers, and HEOR Leads.

3. Early-Stage Market Access Strategy

Focus: Aligning R&D with Return on Investment

Based on the HEMEX series, this session focuses on why market access must be integrated into the earliest stages of drug development. We cover the high cost of development versus the necessity of securing wide patient access through mandatory insurance.

• Key Insight: Moving from sequential tasks to an "Access by Design" architecture.
• Target Audience: Early-stage Founders, VC Associates, and Discovery Teams.